Insider transactions

Keith Crandell

CIK 1219039 · last filed 2026-06-12

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$659.86M
Companies
20
Total Filings
74
Lifetime Open-Market Net
$395.91M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

NMRA price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
8755 W. HIGGINS ROAD
SUITE 1025
CHICAGO, IL 60631
Related Filers
Clinton Bybee — 113 joint filings, latest 2026-07-06
Robert Nelsen — 84 joint filings, latest 2026-07-06
Steven Gillis — 45 joint filings, latest 2026-07-06
ARCH Venture Fund IX Overage, L.P. — 32 joint filings, latest 2025-07-29
ARCH Venture Fund IX, L.P. — 32 joint filings, latest 2025-07-29
ARCH Venture Partners IX Overage, L.P. — 32 joint filings, latest 2025-07-29
ARCH Venture Partners IX, L.P. — 32 joint filings, latest 2025-07-29
ARCH Venture Partners IX, LLC — 32 joint filings, latest 2025-07-29
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MASS Director 5,764,419 $11.65 $67.16M $6.00M 8 2026-06-12
TWST Director 103,618 $145.25 $15.05M -$11.52M 13 2026-02-09
NMRA 10%+ Owner 6,046,907 $0.39 $2.38M $258.64M 5 2025-10-29
LYEL 10%+ Owner 910,317 $9.31 $8.48M $0 1 2025-07-29
SANA 10%+ Owner 12,446,022 $2.36 $29.37M $40.00M 1 2024-02-12
QTRX Director 308,483 $2.83 $873.0K $3.99M 22 2023-04-04
VIR 10%+ Owner 7,563,619 $11.04 $83.50M $0 1 2022-09-07
DA32 Life Science Tech Acquisition Corp. (DALS) Delisted Director 2,250,000 $10.32 $23.22M $16.00M 2 2021-08-09
ADESTO TECHNOLOGIES Corp (IOTS) Delisted Director 1,177,937 — — $2.00M 6 2019-06-06
Syros Pharmaceuticals, Inc. (SYRS) Delisted 10%+ Owner 435,087 $0.00 $174 -$14.59M 2 2019-03-14
Sienna Biopharmaceuticals, Inc. (SNNA) Delisted 10%+ Owner 2,900,575 — — $70.39M 2 2019-02-26
PULM 17,182 $1.44 $24.7K $0 1 2018-04-05
FIXX 10%+ Owner 337,150 $6.93 $2.34M $0 1 2018-04-04
DNLI 10%+ Owner 11,068,749 $18.66 $206.54M $0 1 2017-12-12
XCOM 10%+ Owner — $29.00 — $0 2 2016-10-13
PI 10%+ Owner 1,388,049 $172.23 $239.06M $0 1 2016-07-26
Sage Therapeutics, Inc. (SAGE) Delisted 10%+ Owner 3,187,044 $8.68 $27.66M $0 1 2015-01-16
FATE 10%+ Owner 2,473,188 $2.06 $5.08M $25.00M 1 2013-10-07
KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted 10%+ Owner 1,897,474 — — $0 1 2012-10-16
CELEBRATE EXPRESS, INC. (BDAY) Delisted Director — — — $0 1 2007-10-23

Recent Filings · Page 6 of 8

74 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2019-04-03 QTRX Grant (A) +502 $11.7K EDGAR
2019-03-14 Syros Pharmaceuticals, Inc. (SYRS) Delisted Sell (S) −1,005,018 -$7.87M EDGAR
2019-03-11 Syros Pharmaceuticals, Inc. (SYRS) Delisted Sell (S) −987,498 -$6.71M EDGAR
2019-02-26 Sienna Biopharmaceuticals, Inc. (SNNA) Delisted Buy (P) +15,160,600 $37.90M EDGAR
2019-02-26 Sienna Biopharmaceuticals, Inc. (SNNA) Delisted Buy (P) +12,994,800 $32.49M EDGAR
2019-01-04 QTRX Grant (A) +2,270 $0 EDGAR
2018-11-06 TWST Mixed +3,361,568 $1.05M EDGAR
2018-08-09 QTRX Grant (A) +2,270 $0 EDGAR
2018-07-31 ADESTO TECHNOLOGIES Corp (IOTS) Delisted Grant (A) +3,243 $0 EDGAR
2018-04-05 PULM Buy (P) +8,050,000 $0 EDGAR
Showing 51–60 of 74
Page 6 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.